Dicerna Pharmaceuticals, Inc. clinical trials
Acquired by Novo Nordisk A/S, Dec 28, 2021 · source ↗
The registry lists 18 studies whose lead sponsor is Dicerna Pharmaceuticals, Inc.. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 8, 2026.
Before and after it joined Novo Nordisk A/S
- First submitted before Dicerna Pharmaceuticals, Inc. became part of Novo Nordisk A/S
- 14
- First submitted after Dicerna Pharmaceuticals, Inc. became part of Novo Nordisk A/S
- 4
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company18 studies
Something wrong with this grouping? Tell us on the Novo Nordisk A/S page.
Studies
Recruiting first, then most recently updated. Showing 18 of 18. All Novo Nordisk A/S studies →
- Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRDRecruitingNCT04580420Phase 2
Sponsor listed in the registry: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · First submitted before Dicerna Pharmaceuticals, Inc. became part of Novo Nordisk A/S
- Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid TumorsRecruitingNCT06504368Phase 1
Sponsor listed in the registry: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · First submitted after Dicerna Pharmaceuticals, Inc. became part of Novo Nordisk A/S
- Long Term Extension Study in Patients With Primary HyperoxaluriaActive, not recruitingNCT04042402Phase 3
Sponsor listed in the registry: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · First submitted before Dicerna Pharmaceuticals, Inc. became part of Novo Nordisk A/S
- A Study of DCR-STAT3 in Adults With Solid TumorsCompletedNCT06098651Phase 1
Sponsor listed in the registry: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · First submitted after Dicerna Pharmaceuticals, Inc. became part of Novo Nordisk A/S
- Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal FunctionCompletedNCT05001269Phase 2
Sponsor listed in the registry: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · First submitted before Dicerna Pharmaceuticals, Inc. became part of Novo Nordisk A/S
- A Study of Belcesiran in Patients With AATLDTerminatedNCT04764448Phase 2
Sponsor listed in the registry: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · First submitted before Dicerna Pharmaceuticals, Inc. became part of Novo Nordisk A/S
- Phase 1b Study of DCR-AUD in Healthy VolunteersCompletedNCT05845398Phase 1
Sponsor listed in the registry: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · First submitted after Dicerna Pharmaceuticals, Inc. became part of Novo Nordisk A/S
- Treatment of Primary Hyperoxaluria Type 1 With NedosiranNo longer availableNCT05993416
Sponsor listed in the registry: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · First submitted after Dicerna Pharmaceuticals, Inc. became part of Novo Nordisk A/S
- Study of DCR-AUD in Healthy VolunteersCompletedNCT05021640Phase 1
Sponsor listed in the registry: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · First submitted before Dicerna Pharmaceuticals, Inc. became part of Novo Nordisk A/S
- Natural History of Patients With PH3 and a History of Stone EventsCompletedNCT04542590
Sponsor listed in the registry: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · First submitted before Dicerna Pharmaceuticals, Inc. became part of Novo Nordisk A/S
- Study of DCR-A1AT in Healthy Adult VolunteersCompletedNCT04174118Phase 1
Sponsor listed in the registry: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · First submitted before Dicerna Pharmaceuticals, Inc. became part of Novo Nordisk A/S
- An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD)WithdrawnNCT05146882Phase 2
Sponsor listed in the registry: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · First submitted before Dicerna Pharmaceuticals, Inc. became part of Novo Nordisk A/S
- Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary HyperoxaluriaCompletedNCT03392896Phase 1
Sponsor listed in the registry: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · First submitted before Dicerna Pharmaceuticals, Inc. became part of Novo Nordisk A/S
- Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 PatientsCompletedNCT04555486Phase 1
Sponsor listed in the registry: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · First submitted before Dicerna Pharmaceuticals, Inc. became part of Novo Nordisk A/S
- Study of Safety and Tolerability of DCR HBVSCompletedNCT03772249Phase 1
Sponsor listed in the registry: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · First submitted before Dicerna Pharmaceuticals, Inc. became part of Novo Nordisk A/S
- A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)TerminatedNCT02795325Phase 1
Sponsor listed in the registry: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · First submitted before Dicerna Pharmaceuticals, Inc. became part of Novo Nordisk A/S
- Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or LymphomaTerminatedNCT02110563Phase 1
Sponsor listed in the registry: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · First submitted before Dicerna Pharmaceuticals, Inc. became part of Novo Nordisk A/S
- Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular CarcinomaTerminatedNCT02314052Phase 1/2
Sponsor listed in the registry: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · First submitted before Dicerna Pharmaceuticals, Inc. became part of Novo Nordisk A/S